BLCO · Bausch & Lomb Corp · Executive Compensation

$20.00 -0.40 (-1.96%) At close · Oct 30 Q3 2026 earnings call transcript

Market Cap

$7.15B

357.50M

Volume · Oct 30 1.43M Avg daily vol (3M) 553.46K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brenton L. Saunders	Chairman of the Board and Chief Executive Officer	$1,600,000	—	$23,778,578	$2,799,998	$4,000,000	$15,750	$32,194,326
Sam Eldessouky	Executive Vice President and Chief Financial Officer	$777,981	$250,000	$2,514,714	$659,996	$744,000	$15,750	$4,962,441
A. Robert D. Bailey	Executive Vice President and Chief Legal Officer	$767,942	—	$1,714,561	$449,998	$673,200	$27,250	$3,632,951
Yehia Hashad	Executive Vice President of Research & Development and Chief Medical Officer	$726,116	—	$1,066,839	$279,996	$700,800	$15,750	$2,789,501
Andrew Stewart	President, Global Pharmaceuticals and International Consumer	$629,077	—	$990,631	$259,995	$604,800	$15,750	$2,500,253

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brenton L. Saunders	Chairman of the Board and Chief Executive Officer	$1,600,000	—	$16,106,834	$2,799,997	$3,338,400	$15,525	$23,860,756
Sam Eldessouky	Executive Vice President and Chief Financial Officer	$766,885	—	$4,479,329	$750,000	$829,250	$15,525	$6,840,989
A. Robert D. Bailey	Executive Vice President and Chief Legal Officer	$767,423	—	$3,558,049	$500,000	$687,582	$15,525	$5,528,579
Dr. Yehia Hashad	Executive Vice President of Research & Development and Chief Medical Officer	$696,846	—	$2,867,061	$312,499	$629,160	$20,525	$4,526,091
Yehia Hashad	Executive Vice President of Research & Development and Chief Medical Officer	$696,846	—	$2,867,061	$312,499	$629,160	$20,525	$4,526,091
Andrew Stewart	President, Global Pharmaceuticals and International Consumer	$616,269	—	$2,636,714	$250,000	$552,762	$26,525	$4,082,270

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brenton L. Saunders	Chairman of the Board and Chief Executive Officer	$1,396,923	$6,500,000	$27,870,000	$7,305,493	$2,181,436	$55,199	$45,309,051
Joseph Papa	Former Chief Executive Officer	$283,077	—	—	—	—	$9,245,009	$9,528,086
Christina M. Ackermann	Former Executive Vice President & General Counsel and President Ophthalmic Pharmaceuticals	$246,635	$250,000	$1,791,652	$499,999	$205,766	$3,096,961	$6,091,013
Joseph F. Gordon	Former President Global Consumer, Surgical and Vision Care	$559,800	$250,000	$1,343,745	$375,000	$465,938	$2,265,647	$5,260,130
A. Robert D. Bailey	Executive Vice President and Chief Legal Officer	$519,231	$200,000	$2,049,705	$1,999,997	$430,816	$14,850	$5,214,599
Sam Eldessouky	Executive Vice President and Chief Financial Officer	$710,769	—	$2,687,500	$749,999	$594,048	$14,850	$4,757,166
Yehia Hashad	Executive Vice President of Research & Development and Chief Medical Officer	$660,000	—	$1,119,765	$312,500	$551,616	$13,613	$2,657,494
Dr. Yehia Hashad	Executive Vice President of Research & Development and Chief Medical Officer	$660,000	—	$1,119,765	$312,500	$551,616	$13,613	$2,657,494
Andrew Stewart	President, Global Pharmaceuticals and International Consumer	$415,385	$600,000	$563,882	—	$344,653	$9,346	$1,933,266

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph Papa	Former Chief Executive Officer	$1,600,000	—	$8,499,996	$8,499,996	$1,128,000	$53,769	$19,781,761
Sam Eldessouky	Executive Vice President and Chief Financial Officer	$700,000	—	$2,813,150	$2,249,998	$375,200	$13,725	$6,152,073
Christina M. Ackermann	Former Executive Vice President & General Counsel and President Ophthalmic Pharmaceuticals	$750,000	—	$2,063,144	$1,499,999	$402,000	$20,383	$4,735,526
Joseph Gordon	—	$600,000	—	$1,813,142	$1,249,999	$321,600	$13,882	$3,998,623
Joseph F. Gordon	Former President Global Consumer, Surgical and Vision Care	$600,000	—	$1,813,142	$1,249,999	$321,600	$13,882	$3,998,623
Dr. Yehia Hashad	Executive Vice President of Research & Development and Chief Medical Officer	$602,500	—	$1,188,146	$624,997	$319,764	$117,386	$2,852,793

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph Papa	Former Chief Executive Officer	$1,600,000	—	$16,561,105	$2,250,054	$2,448,000	$29,978	$22,889,137
Christina M. Ackermann	Former Executive Vice President & General Counsel and President Ophthalmic Pharmaceuticals	$750,000	—	$2,348,225	$600,033	$862,000	$14,330	$4,574,588
Sam Eldessouky	Executive Vice President & Chief Financial Officer	$620,385	—	$1,778,793	$1,187,756	$731,950	$13,340	$4,332,224
Joseph Gordon	—	$600,000	—	$1,507,810	$375,066	$739,600	$18,050	$3,240,526
Joseph F. Gordon	Former President Global Consumer, Surgical and Vision Care	$600,000	—	$1,507,810	$375,066	$739,600	$18,050	$3,240,526

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Joseph Papa	Chief Executive Officer	$1,526,539	—	$8,127,907	$2,251,352	$2,160,000	$53,563	$14,119,361
Christina M. Ackermann	Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals	$743,654	—	$1,692,387	$540,362	$540,000	$24,625	$3,541,028
Joseph F. Gordon	President, Global Consumer, Surgical and Vision Care	$597,346	—	$785,420	$375,263	$432,000	$17,825	$2,207,854
Joseph Gordon	—	$597,346	—	$785,420	$375,263	$432,000	$17,825	$2,207,854
Sam Eldessouky	Executive Vice President & Chief Financial Officer	$500,000	—	$392,709	$187,631	$225,000	$12,825	$1,318,165

Executive changes

Person	Role	Change	Effective	Filed
Nathalie Bernier	Board of Directors of the Company	Resigned	2026-10-28	2026-10-28
Brenton L. Saunders	each and every other position I hold with the Company or any of its subsidiaries or affiliates, whether as a director, manager,	Resigned	2026-10-12	2026-10-13
Brenton L. Saunders	director	Resigned	2026-10-12	2026-10-13
Brenton L. Saunders	Chief Executive Officer	Resigned	2026-10-12	2026-10-13
Thomas J. Appio	interim Chief Executive Officer	Appointed	2026-10-12	2026-10-13
Brent Saunders	member of the Company's board of directors	Resigned	2026-10-12	2026-10-13
Brent Saunders	Chief Executive Officer	Resigned	2026-10-12	2026-10-13
Andrew C. von Eschenbach, M.D.	Board	Resigned	2026-08-05	2026-08-06
Steven H. Collis	Board	Resigned	2026-08-05	2026-08-06
Karen L. Ling	Board	Resigned	2026-08-05	2026-08-06
Thomas W. Ross, Sr.	Board	Resigned	2026-08-05	2026-08-06
Laurence Paul, M.D.	board of directors	Appointed	2026-08-05	2026-08-06
Barbara Trebbi	board of directors	Appointed	2026-08-05	2026-08-06
Robert Chersi	board of directors	Appointed	2026-08-05	2026-08-06
Thomas J. Appio	board of directors	Appointed	2026-08-05	2026-08-06
Steven H. Collis	board of directors	Appointed	2026-01-01	2025-12-17
Eduardo C. Alfonso	board of directors	Appointed	2026-01-01	2025-12-17
Gary Hu	board of directors	Resigned	2025-08-14	2025-08-18
Brett Icahn	board of directors	Resigned	2025-08-14	2025-08-18
Brenton L. Saunders	Director	Appointed	2024-05-29	2024-05-29
Andrew C. von Eschenbach	Director	Appointed	2024-05-29	2024-05-29
Thomas W. Ross, Sr.	Director	Appointed	2024-05-29	2024-05-29
Russel C. Robertson	Director	Appointed	2024-05-29	2024-05-29
John A. Paulson	Director	Appointed	2024-05-29	2024-05-29
Sarah B. Kavanagh	Director	Appointed	2024-05-29	2024-05-29

Leadership

Thomas J. Appio CEO, Board Member
Brent Saunders Chairman
Thomas W. Ross, Sr. Chairman, Board Member
Sam Eldessouky CFO
A. Robert D. Bailey General Counsel
Christina M. Ackermann General Counsel
Andrew C. von Eschenbach Board Member
Barbara Trebbi Board Member
Brett Icahn Board Member
Eduardo C. Alfonso Board Member
Gary Hu Board Member
John A. Paulson Board Member
Karen L. Ling Board Member
Karen Ling Board Member
Laurence Paul Board Member
Laurence Paul, M.D. Board Member
Robert Chersi Board Member
Russel C. Robertson Board Member
Sarah B. Kavanagh Board Member
Steven H. Collis Board Member

Key facts CIK 1860742 CUSIP 071705107 13F (30d) 13 filings 13 filers Visit website Investor relations